Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum

Amit Kaura; Adam J W Trickey; Anoop S V Shah; Umberto Benedetto; Ben Glampson; Abdulrahim Mulla; Luca Mercuri; Sanjay Gautama; Ceire E Costelloe; Ian Goodman; Julian Redhead; Kavitha Saravanakumar; E Mayer; Jamil   Mayet

doi:10.1016/j.eclinm.2022.101344

Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum

Amit Kaura, Adam J W Trickey, Anoop S V Shah, Umberto Benedetto, Ben Glampson, Abdulrahim Mulla, Luca Mercuri, Sanjay Gautama, Ceire E Costelloe, Ian Goodman, Julian Redhead, Kavitha Saravanakumar, E Mayer, Jamil Mayet

Research output: Contribution to journal › Article (Academic Journal) › peer-review

22 Citations (Scopus)

78 Downloads (Pure)

Original language	English
Article number	101344
Journal	eClinicalMedicine
Volume	46
Early online date	12 Mar 2022
DOIs	https://doi.org/10.1016/j.eclinm.2022.101344
Publication status	E-pub ahead of print - 12 Mar 2022

Bibliographical note

Funding Information:
This research was enabled by the iCARE environment and WSIC team and data resources (https://imperialbrc.nihr.ac.uk/facilities/icare/). The research was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC), the NIHR Imperial Patient Safety Translational Research Centre and the NWL NIHR Applied Research Collaboration. AK is funded by a British Heart Foundation clinical research training fellowship (FS/20/18/34972). AT is funded by a Sir Henry Wellcome Postdoctoral Fellowship (222770/Z/21/Z). JM is supported by the BHF Imperial Centre for Research Excellence (RE/18/4/34215). All other authors have none to declare.

Funding Information:
National Institute for Health Research Imperial Biomedical Research Centre, British Heart Foundation and Wellcome Trust.

Funding Information:
The authors would like to acknowledge members of the NWL Data & Analytics Gold Command for contribution to interpretation of the findings; Roger Chinn, Martin Kuper, Merav Dover, James Biggin-Lamming, Sanjay Gautama, Kevin Jarrold. The authors would also like to acknowledge Owain Griffiths from WSIC for helping with data access and data quality checks. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Publisher Copyright:
© 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.eclinm.2022.101344Licence: CC BY-NC-ND

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Elsevier at https://doi.org/10.1016/j.eclinm.2022.101344 . Please refer to any applicable terms of use of the publisher.
Final published version, 1.56 MBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

Kaura, A., Trickey, A. J. W., Shah, A. S. V., Benedetto, U., Glampson, B., Mulla, A., Mercuri, L., Gautama, S., Costelloe, C. E., Goodman, I., Redhead, J., Saravanakumar, K., Mayer, E., & Mayet, J. (2022). Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum. eClinicalMedicine, 46, Article 101344. Advance online publication. https://doi.org/10.1016/j.eclinm.2022.101344

@article{b39ff59eeb4c42d7a39454ed45f8c45a,

title = "Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum",

author = "Amit Kaura and Trickey, \{Adam J W\} and Shah, \{Anoop S V\} and Umberto Benedetto and Ben Glampson and Abdulrahim Mulla and Luca Mercuri and Sanjay Gautama and Costelloe, \{Ceire E\} and Ian Goodman and Julian Redhead and Kavitha Saravanakumar and E Mayer and Jamil Mayet",

note = "Funding Information: This research was enabled by the iCARE environment and WSIC team and data resources (https://imperialbrc.nihr.ac.uk/facilities/icare/). The research was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC), the NIHR Imperial Patient Safety Translational Research Centre and the NWL NIHR Applied Research Collaboration. AK is funded by a British Heart Foundation clinical research training fellowship (FS/20/18/34972). AT is funded by a Sir Henry Wellcome Postdoctoral Fellowship (222770/Z/21/Z). JM is supported by the BHF Imperial Centre for Research Excellence (RE/18/4/34215). All other authors have none to declare. Funding Information: National Institute for Health Research Imperial Biomedical Research Centre, British Heart Foundation and Wellcome Trust. Funding Information: The authors would like to acknowledge members of the NWL Data \& Analytics Gold Command for contribution to interpretation of the findings; Roger Chinn, Martin Kuper, Merav Dover, James Biggin-Lamming, Sanjay Gautama, Kevin Jarrold. The authors would also like to acknowledge Owain Griffiths from WSIC for helping with data access and data quality checks. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = mar,

day = "12",

doi = "10.1016/j.eclinm.2022.101344",

language = "English",

volume = "46",

journal = "eClinicalMedicine",

issn = "2589-5370",

publisher = "Elsevier Limited",

}

Kaura, A, Trickey, AJW, Shah, ASV, Benedetto, U, Glampson, B, Mulla, A, Mercuri, L, Gautama, S, Costelloe, CE, Goodman, I, Redhead, J, Saravanakumar, K, Mayer, E & Mayet, J 2022, 'Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum', eClinicalMedicine, vol. 46, 101344. https://doi.org/10.1016/j.eclinm.2022.101344

TY - JOUR

T1 - Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum

AU - Kaura, Amit

AU - Trickey, Adam J W

AU - Shah, Anoop S V

AU - Benedetto, Umberto

AU - Glampson, Ben

AU - Mulla, Abdulrahim

AU - Mercuri, Luca

AU - Gautama, Sanjay

AU - Costelloe, Ceire E

AU - Goodman, Ian

AU - Redhead, Julian

AU - Saravanakumar, Kavitha

AU - Mayer, E

AU - Mayet, Jamil

N1 - Funding Information: This research was enabled by the iCARE environment and WSIC team and data resources (https://imperialbrc.nihr.ac.uk/facilities/icare/). The research was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC), the NIHR Imperial Patient Safety Translational Research Centre and the NWL NIHR Applied Research Collaboration. AK is funded by a British Heart Foundation clinical research training fellowship (FS/20/18/34972). AT is funded by a Sir Henry Wellcome Postdoctoral Fellowship (222770/Z/21/Z). JM is supported by the BHF Imperial Centre for Research Excellence (RE/18/4/34215). All other authors have none to declare. Funding Information: National Institute for Health Research Imperial Biomedical Research Centre, British Heart Foundation and Wellcome Trust. Funding Information: The authors would like to acknowledge members of the NWL Data & Analytics Gold Command for contribution to interpretation of the findings; Roger Chinn, Martin Kuper, Merav Dover, James Biggin-Lamming, Sanjay Gautama, Kevin Jarrold. The authors would also like to acknowledge Owain Griffiths from WSIC for helping with data access and data quality checks. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Publisher Copyright: © 2022

PY - 2022/3/12

Y1 - 2022/3/12

UR - https://www.sciencedirect.com/science/article/pii/S2589537022000748

U2 - 10.1016/j.eclinm.2022.101344

DO - 10.1016/j.eclinm.2022.101344

M3 - Article (Academic Journal)

C2 - 35295900

SN - 2589-5370

VL - 46

JO - eClinicalMedicine

JF - eClinicalMedicine

M1 - 101344

ER -

Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum

Bibliographical note

UN SDGs

Access to Document

Handle.net

Other files and links

Cite this